PPARG and metabolic dysfunction-associated steatohepatitis: Since PPARγ activation plays a protective role in NASH pathogenesis, including attenuation of hepatic inflammation, hepatocyte apoptosis, liver injury, and fibrosis [40–42], we speculate that IGF2BP2 may promote steatohepatitis through PPARγ-independent mechanisms.